{"id":"NCT00996281","sponsor":"Takeda","briefTitle":"Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension","officialTitle":"A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose Combination in Subjects With Essential Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2011-11","completion":"2011-11","firstPosted":"2009-10-16","resultsPosted":"2012-11-12","lastUpdate":"2012-11-12"},"enrollment":837,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Essential Hypertension"],"interventions":[{"type":"DRUG","name":"Azilsartan medoxomil and chlorthalidone","otherNames":["TAK-491CLD"]},{"type":"DRUG","name":"Olmesartan medoxomil and hydrochlorothiazide","otherNames":["Benicar HCT®","Olmetec Plus®"]}],"arms":[{"label":"Azilsartan Medoxomil and Chlorthalidone","type":"EXPERIMENTAL"},{"label":"Olmesartan Medoxomil and Hydrochlorothiazide QD","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the safety and tolerability of azilsartan medoxomil plus chlorthalidone, once daily (QD), versus olmesartan medoxomil-hydrochlorothiazide in adults with essential hypertension.","primaryOutcome":{"measure":"Percentage of Participants With at Least 1 Adverse Event","timeFrame":"From Week 0 (Day 1) to Week 52.","effectByArm":[{"arm":"Azilsartan Medoxomil and Chlorthalidone","deltaMin":78.5,"sd":null},{"arm":"Olmesartan Medoxomil and Hydrochlorothiazide","deltaMin":76.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":17},"locations":{"siteCount":26,"countries":["Austria","Germany","Netherlands","Poland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":418},"commonTop":["Blood creatinine increased","Dizziness","Nasopharyngitis","Headache","Upper respiratory tract infection"]}}